X
41.48
-0.14 (-0.34%)
| Penutupan Terdahulu | 41.62 |
| Buka | 41.82 |
| Jumlah Dagangan | 763,832 |
| Purata Dagangan (3B) | 865,359 |
| Modal Pasaran | 3,205,367,296 |
| Harga / Jualan (P/S) | 448.11 |
| Harga / Buku (P/B) | 5.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Operasi (TTM) | -969.84% |
| EPS Cair (TTM) | -3.22 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.23% |
| Nisbah Semasa (MRQ) | 17.66 |
| Aliran Tunai Operasi (OCF TTM) | -196.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -128.49 M |
| Pulangan Atas Aset (ROA TTM) | -22.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Xenon Pharmaceuticals Inc. | Menaik | Menaik |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.13 |
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.14% |
| % Dimiliki oleh Institusi | 103.51% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 5,400,000 |
| Holocene Advisors, Lp | 30 Sep 2025 | 1,976,553 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 62.00 (JP Morgan, 49.47%) | Beli |
| Median | 55.00 (32.59%) | |
| Rendah | 48.00 (Wells Fargo, 15.72%) | Beli |
| Purata | 55.00 (32.59%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 42.91 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 09 Jan 2026 | 62.00 (49.47%) | Beli | 42.15 |
| 18 Nov 2025 | 60.00 (44.65%) | Beli | 40.61 | |
| Wells Fargo | 11 Dec 2025 | 48.00 (15.72%) | Beli | 43.66 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Jan 2026 | Pengumuman | Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Pengumuman | Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Pengumuman | Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 05 Dec 2025 | Pengumuman | Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 |
| 04 Dec 2025 | Pengumuman | Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Dec 2025 | Pengumuman | Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 |
| 25 Nov 2025 | Pengumuman | Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |